HC Wainwright Reaffirms “Buy” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)

HC Wainwright reiterated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $40.00 target price on the stock.

A number of other research firms also recently weighed in on DAWN. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their target price for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.71.

Day One Biopharmaceuticals Stock Down 0.5 %

DAWN stock opened at $14.65 on Thursday. Day One Biopharmaceuticals has a twelve month low of $10.90 and a twelve month high of $18.07. The company has a market cap of $1.29 billion, a P/E ratio of -14.22 and a beta of -1.51. The business’s fifty day moving average is $14.19 and its 200-day moving average is $14.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter last year, the company posted ($0.54) EPS. Research analysts anticipate that Day One Biopharmaceuticals will post -1.65 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now owns 26,928 shares of the company’s stock, valued at approximately $376,992. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Adam Dubow sold 3,202 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now directly owns 26,928 shares in the company, valued at approximately $376,992. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,748 shares of company stock valued at $689,072 in the last quarter. Insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares during the period. ProShare Advisors LLC boosted its holdings in Day One Biopharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock worth $287,000 after buying an additional 1,447 shares during the period. SteelPeak Wealth LLC boosted its stake in shares of Day One Biopharmaceuticals by 9.8% in the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after acquiring an additional 1,550 shares during the period. Handelsbanken Fonder AB grew its holdings in Day One Biopharmaceuticals by 16.9% during the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after buying an additional 3,900 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in Day One Biopharmaceuticals by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock valued at $887,000 after acquiring an additional 5,070 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.